News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Paul Newman

Advertisement

Articles by Paul Newman

Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs

ByPaul Newman,William Kimmerle
March 24th 2021

NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.

Advertisement

Latest Updated Articles

  • Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs
    Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs

    March 24th 2021



Advertisement
Advertisement

Trending on PharmExec

1

Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection

2

When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026

3

Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals

4

FDA Reveals New Guidance for Streamlining Biosimilar Development

5

What Risks and Opportunities Does FDA's Single-Trial Approval Pathway Create?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us